Arcturus therapeutics & duke-nus receive approval to proceed with phase 1/2 clinical trial for covid-19 vaccine candidate

Arcturus therapeutics & duke-nus received approval to proceed with phase 1/2 clinical trial for covid-19 vaccine candidate, lunar-cov19.arcturus therapeutics holdings inc - human dosing of lunar-cov19 expected soon.arcturus therapeutics - differentiated starr mrna vaccine expected to produce humoral and cellular immunity at very low doses.arcturus therapeutics - new preclinical data demonstrates neutralizing antibody titers continue to increase for 50 days after single administration.arcturus therapeutics holdings inc - arcturus & duke-nus will initiate human dosing of lunar-cov19 as soon as possible.
ARCT Ratings Summary
ARCT Quant Ranking